Newstral
Article
Bbarrons.com on 2022-02-02 12:19
Novartis Earnings Rise, Says Review of Sandoz Unit Progressing2 min read
Related news
- Novartis mulls spinning off Sandoz generic drug unittimesofmalta.com
- BNovartis Looks Appealing, Based on Strong Drug Pipeline and Planned Sandoz Spinoff4 min readbarrons.com
- MNovartis hemoglobinuria trial meets two primary endpoints1 min readmarketwatch.com
- Novartis-Tochter Sandoz bekommt neuen ChefReuters
- BNovartis CEO Vasant Narasimhan Sees Consistent Growth While Sitting on Cash4 min readbarrons.com
- BNovartis Will Cut Up to 8,000 Jobs Under CEO's Shake-Up Plan1 min readbarrons.com
- MNovartis sales and profit drop, but backs 2022 guidance1 min readmarketwatch.com
- BNovartis CEO Continues His Shake-Up, Says It Will Save More Than $1 Billion Annually3 min readbarrons.com
- MNovartis prostate cancer drug trial meets primary endpoint1 min readmarketwatch.com
- MABB completes spinoff of turbocharging unit Accelleron1 min readmarketwatch.com
- BUBS Revamps Wealth Unit Catering to Ultrawealthy1 min readbarrons.com
- BNovartis Stock Is Rising as Earnings Inch Past Forecastsbarrons.com
- Novartis unit to start selling copy of Amgen drug NeupogenLA Times
- Novartis AG: Novartis plans to spin off Sandoz in OctoberFinancial Times
- BNovartis to Spend Bulk of Roche Windfall on Buying Back Stock, Not M&A3 min readbarrons.com
- MNovartis's Sandoz to buy Glaxo antibiotics unitmarketwatch.com
- Novartis Earnings Fall on Slide in Cancer-Drug Saleswsj.com
- GSK sees drop in earnings after asset swap with Novartisreviewtimes.com